Atrial fibrillation raises stroke risk fivefold. But what if blood thinners are too dangerous after a brain bleed or major fall? A new monthly injection, abelacimab, may prevent strokes without the bleeding risk of traditional anticoagulants. Is this the future for AFib patients who can’t take blood thinners? Cardiologist Dr. Alain Bouchard discusses this groundbreaking drug with Dr. Charles V. Pollack, a consultant clinical scientist and professional educator with Novartis, owner of abelac...
All content for MyHeart.net is the property of Dr. Alain Bouchard and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Atrial fibrillation raises stroke risk fivefold. But what if blood thinners are too dangerous after a brain bleed or major fall? A new monthly injection, abelacimab, may prevent strokes without the bleeding risk of traditional anticoagulants. Is this the future for AFib patients who can’t take blood thinners? Cardiologist Dr. Alain Bouchard discusses this groundbreaking drug with Dr. Charles V. Pollack, a consultant clinical scientist and professional educator with Novartis, owner of abelac...
In the last 15 years, the landscape of diabetes and obesity management has been significantly transformed by the advent of GLP-1 receptor agonists which are about to become the most successful drugs in the history of medicine, eclipsing drugs like insulin and statin. Dr Alain Bouchard, MD discusses with Dr. Timothy Garvey, Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham.
MyHeart.net
Atrial fibrillation raises stroke risk fivefold. But what if blood thinners are too dangerous after a brain bleed or major fall? A new monthly injection, abelacimab, may prevent strokes without the bleeding risk of traditional anticoagulants. Is this the future for AFib patients who can’t take blood thinners? Cardiologist Dr. Alain Bouchard discusses this groundbreaking drug with Dr. Charles V. Pollack, a consultant clinical scientist and professional educator with Novartis, owner of abelac...
